Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (431-440 of 610) with videos related to

Pageof 61
Sort By:
Cancer Treatment Reviews|January 21, 2017
Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug developmentRicardo Costa, Ami N Shah, Cesar A Santa-Maria, et al.
Blood|December 21, 2006
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLZhihong Zeng, Dos D Sarbassov, Ismael J Samudio, et al.
Scientific Reports|September 14, 2016
Aspect-ratio driven evolution of high-order resonant modes and near-field distributions in localized surface phonon polariton nanostructuresChase T Ellis, Joseph G Tischler, Orest J Glembocki, et al.
Haematologica|May 9, 2020
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancersThomas Lewis, David B Corcoran, David E Thurston, et al.
Blood|November 8, 2003
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignanciesJean-Pierre J Issa, Guillermo Garcia-Manero, Francis J Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2014
Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targetingJessica K Altman, Amy Szilard, Dennis J Goussetis, et al.
International Journal of Laboratory Hematology|January 15, 2008
Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemiaI Jilani, C Wei, B N Bekele, et al.
Science (New York, N.Y.)|April 26, 2014
The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewalMarcela Rosas, Luke C Davies, Peter J Giles, et al.
Leukemia|November 15, 2011
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up resultsP D le Coutre, F J Giles, A Hochhaus, et al.
Journal of Applied Gerontology : the Official Journal of the Southern Gerontological Society|March 22, 2014
Independent Living Oldest Old and Their Primary Health Provider: A Mixed Method Examination of the Influence of Patient Personality CharacteristicsLee M Stadtlander, Martha J Giles, Amy E Sickel, et al.
Pageof 61

Showing results (431-440 of 610) with videos related to

Sort By:
Pageof 61
Cancer Treatment Reviews|January 21, 2017
Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug developmentRicardo Costa, Ami N Shah, Cesar A Santa-Maria, et al.
Blood|December 21, 2006
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLZhihong Zeng, Dos D Sarbassov, Ismael J Samudio, et al.
Scientific Reports|September 14, 2016
Aspect-ratio driven evolution of high-order resonant modes and near-field distributions in localized surface phonon polariton nanostructuresChase T Ellis, Joseph G Tischler, Orest J Glembocki, et al.
Haematologica|May 9, 2020
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancersThomas Lewis, David B Corcoran, David E Thurston, et al.
Blood|November 8, 2003
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignanciesJean-Pierre J Issa, Guillermo Garcia-Manero, Francis J Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2014
Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targetingJessica K Altman, Amy Szilard, Dennis J Goussetis, et al.
International Journal of Laboratory Hematology|January 15, 2008
Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemiaI Jilani, C Wei, B N Bekele, et al.
Science (New York, N.Y.)|April 26, 2014
The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewalMarcela Rosas, Luke C Davies, Peter J Giles, et al.
Leukemia|November 15, 2011
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up resultsP D le Coutre, F J Giles, A Hochhaus, et al.
Journal of Applied Gerontology : the Official Journal of the Southern Gerontological Society|March 22, 2014
Independent Living Oldest Old and Their Primary Health Provider: A Mixed Method Examination of the Influence of Patient Personality CharacteristicsLee M Stadtlander, Martha J Giles, Amy E Sickel, et al.
Pageof 61